Neutralizing antibodies that bind to the HIV-1 Env V2 critical neutralization domain
US9796773B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Aug 19, 2014 |
| Grant date | Oct 24, 2017 |
| Priority date | — |
| Expiry date | Nov 26, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against a broad spectrum of HIV-1 isolates. The polypeptides, variants, and fragments include a portion of the gp120 V2 domain of HIV-1. The polypeptides, variants, and fragments display an epitope that is recognized by at least one antibody which neutralizes at least one HIV-1 primary isolate. This invention also features nucleic acid sequences encoding those polypeptides. In addition, the invention provides methods of screening for inhibitors of HIV-1 entry into cells, as well as methods of treatment using the inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.